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Lysine insertion during coded protein synthesis re-
quires lysyl-tRNALys, which is synthesized by lysyl-tRNA
synthetase (LysRS). Two unrelated forms of LysRS are
known: LysRS2, which is found in eukaryotes, most bac-
teria, and a few archaea, and LysRS1, which is found in
most archaea and a few bacteria. To compare amino acid
recognition between the two forms of LysRS, the effects
of L-lysine analogues on aminoacylation were investi-
gated. Both enzymes showed stereospecificity toward
the L-enantiomer of lysine and discriminated against
noncognate amino acids with different R-groups (argi-
nine, ornithine). Lysine analogues containing substitu-
tions at other positions were generally most effective as
inhibitors of LysRS2. For example, the Ki values for
aminoacylation of S-(2-aminoethyl)-L-cysteine and L-ly-
sinamide were over 180-fold lower with LysRS2 than
with LysRS1. Of the other analogues tested, only -ami-
nobutyric acid showed a significantly higher Ki for Ly-
sRS2 than LysRS1. These data indicate that the lysine-
binding site is more open in LysRS2 than in LysRS1, in
agreement with previous structural studies. The physi-
ological significance of divergent amino acid recogni-
tion was reflected by the in vivo resistance to growth
inhibition imparted by LysRS1 against S-(2-amino-
ethyl)-L-cysteine and LysRS2 against -aminobutyric
acid. These differences in resistance to naturally occur-
ring noncognate amino acids suggest the distribution of
LysRS1 and LysRS2 contributes to quality control dur-
ing protein synthesis. In addition, the specific inhibition
of LysRS1 indicates it is a potential drug target.
The fidelity of coded protein synthesis is dependent on the
accuracy of two processes: the matching of codons in mRNA
with their corresponding anticodons in tRNA and the amino-
acylation of these tRNAs with amino acids defined by the
anticodon. Aminoacyl-tRNA synthesis is a highly specific reac-
tion catalyzed by the aminoacyl-tRNA synthetase (aaRS)1 pro-
tein family, each member of which is specific for a particular
amino acid and tRNA (1, 2). Despite the remarkable precision
aaRSs display in the recognition and selection of the correct
amino acid and tRNA, proofreading and editing mechanisms
are both required to maintain accuracy at a level consistent
with faithful translation of the genetic code (3, 4). Elongation
factor Tu, which takes aminoacyl-tRNAs to the ribosomal de-
coding site, provides an additional level of quality control by
screening for incorrectly aminoacylated tRNAs (5).
The 20 aaRS proteins, as for example found in Escherichia
coli (6), are divided into two mutually exclusive structural
groups of 10 members each termed class I and class II (7, 8).
Structural studies have shown that in class I synthetases, the
active site contains a Rossmann dinucleotide-binding domain,
whereas this fold is absent from the active site of class II
enzymes, which instead contain a novel anti-parallel -fold.
One result of this difference in active site structure is that class
I enzymes bind ATP in an extended conformation and class II
in a bent conformation (7). The other major difference between
the two aaRS classes is in their binding of tRNA and the site at
which the amino acid is subsequently attached to it. With a few
exceptions, class I enzymes approach the acceptor stem of
tRNA from the minor groove side and acylate the 2-hydroxyl of
the terminal adenosine, whereas class II synthetases approach
the major groove side and acylate the 3-hydroxyl (9).
The assignment of an aaRS specific for a particular amino
acid to one or the other structural class is almost completely
conserved in all species, reflecting the antiquity of this dichot-
omy (10). The only widespread exception observed to date is
LysRS, which is found in both class I and class II (11). Com-
parative genomic analysis has established that class I LysRSs
are present in most archaea, a few bacteria, but no eukaryotes
(12). As a result of microbial genome sequencing, over 40 class
I LysRSs have now been identified. Despite their comparative
rarity, class I LysRSs conform to the canonical archaeal/bacte-
rial division of the universal phylogenetic tree (13, 14). Strik-
ingly, the class I (LysRS1) and class II (LysRS2) proteins are
almost never found together, with organisms generally con-
taining one or the other but not both. The only well documented
example of the co-existence of LysRS1 and LysRS2 is in the
Methanosarcinaceae, where they function together to amino-
acylate the specialized tRNAPyl suppressor species (15).
Functional (16) and structural (17) characterizations have
shown that LysRS1 and LysRS2 are functionally equivalent
but structurally unrelated. Consequently, despite their lack of
sequence similarity, the class I and II LysRSs are able to
recognize the same amino acid and tRNA substrates both in
vitro and in vivo, providing an example of functional conver-
gence by divergent enzymes (12). The two classes of LysRS
proteins approach their RNA substrates from opposite sides
but recognize the same regions of tRNALys, namely the antic-
odon, acceptor stem, and discriminator base (16). Within these
common recognition sites in tRNALys, the relative importance
of particular nucleotides varies for the two classes of LysRS
(12). These results show how the unrelated forms of LysRS
perform the same cellular function, in this case tRNALys rec-
ognition, using different molecular mechanisms.
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Variation between LysRS1 and LysRS2 has also been ob-
served for lysine activation. LysRS2 initiates lysyl-tRNA syn-
thesis using only lysine and ATP to generate an enzyme bound
aminoacyl-adenylate, as do all class II and the majority of class
I aaRSs, whereas the class I LysRS requires tRNALys binding
prior to aminoacyl-adenylate synthesis, a feature shared by
only a small sub-group of class I aaRSs (16, 18–20). Crystal
structures of LysRS1 and LysRS2 complexed with L-lysine re-
veal that, whereas their active site architectures are funda-
mentally different, the strategies for recognition of the R-group
of L-lysine (but not the remainder of the molecule) are quite
similar (17). To compare the amino acid recognition strategies
of LysRS1 and LysRS2 in more detail, we have now studied the
effects of L-lysine analogues on the aminoacylation reaction in
vitro and in vivo. Significant differences in substrate recogni-
tion were found, providing both a rationale for the existence of
two forms of LysRS and also suggesting a means of developing
LysRS1 as a species-specific target for novel anti-infective
agents.
EXPERIMENTAL PROCEDURES
Bacterial Strains and Plasmids—Plasmid pKS-lysS (21) was used as
the template for amplification of the E. coli lysS gene, with primers
designed to generate a product flanked by NdeI and SapI sites. PCR
was carried out using Platinum Pfx DNA polymerase (Stratagene) and
the resulting product cloned into the TOPO-TA blunt end (Invitrogen).
The gene was sequenced with two times coverage. Subsequently, the
gene was excised and inserted into the pTYB1 vector to allow produc-
tion of a LysRS2-intein fusion protein (IMPACT System, New England
Biolabs). Bacillus subtilis strain 168 (encoding B. subtilis LysRS2) and
its derivative 157.1 (encoding Borrelia burgdorferi LysRS1 but not B.
subtilis LysRS2) have been described previously (22). The cells were
routinely grown aerobically in LB medium or in Spizizen’s minimal
medium at 37 °C (23).
Substrates—All lysine analogues and other amino acids were from
Sigma except for L-lysine methyl ester and L-lysine ethyl ester (ICN
Biomedical), DL-5-hydroxylysine (Fluka, Buchs, Switzerland) and 5-O-
[N-(L-lysyl)-sulfamoyl] adenosine (RNA-TEC, Leuven, Belgium). All
substrates tested as inhibitors of aminoacylation, with the exception of
D-lysine, were shown by mass spectrometry (Campus Chemical Instru-
ment Center, Ohio State University, Columbus, OH) to lack contami-
nation with lysine. L-[U-14C]lysine and L-[U-3H]lysine were from
PerkinElmer Life Sciences. Transcripts corresponding to B. burgdorferi
tRNALys1 were prepared as described previously (16)
Lysyl-tRNA Synthetase Purification—The E. coli lysS encoded Ly-
sRS2 cloned into the pTYB1 vector was expressed in E. coli BL21(DE3)
cells. Transformants were grown at room temperature in LB supple-
mented with ampicillin (100 g/ml) to cell density A600  0.6. Expres-
sion of lysS was induced by isopropyl-1-thio--D-galactopyranoside (1
mM) for 16 h at room temperature. Subsequent steps were performed at
4 °C. The cells were harvested by centrifugation and washed in column
buffer (20 mM Tris-HCl, pH 7.4, 500 mM NaCl, 1 mM MgCl2, 10%
glycerol). The cells were resuspended in column buffer supplemented
with protease inhibitor (Hoffmann-La Roche), passed through a French
pressure cell, and then centrifuged at 20,000  g for 30 min. The
resulting supernatant was loaded onto a chitin affinity bead column
(New England Biolabs) according to the manufacturer’s instructions.
Protein was eluted from the chitin affinity column in a buffer of 50 mM
Tris-HCl, pH 8.0, 1 mM MgCl2, 50 mM NaCl, 10% glycerol, and 10 mM
-mercaptoethanol. The fractions containing LysRS2 (judged to be
99% pure by Coomassie Blue staining after SDS-PAGE) were pooled,
concentrated by ultrafiltration using Amicon Ultra-15 (Millipore), dia-
lyzed against storage buffer (50 mM Tris-HCl, pH 8.0, 1 mM MgCl2, 10%
glycerol, 10 mM -mercaptoethanol), and stored at 80 °C. The concen-
tration of LysRS2 was determined by active site titration as described
previously (24), except that [14C]tyrosine was replaced with [14C]lysine,
and reactions were performed for 10 min. Calculations were based upon
half of the sites’ reactivity for E. coli LysRS (25). B. burgdorferi LysRS1
was prepared as described previously (16).
Aminoacylation Assays—Aminoacylation was performed at 37 °C in
100 mM Hepes, pH 7.2, 25 mM KCl, 10 mM MgCl2, 4 mM dithiothreitol,
5 mM ATP, 5 M tRNA tRNALys, 100 nM (LysRS1) or 10 nM (LysRS2)
enzyme and [14C]L-Lys at concentrations varying between 0.2 and 5
times the Km. 10 (LysRS2)- or 20-l (LysRS1) aliquots were taken every
15–30 s and spotted onto Whatman No. 3MM filter disks presoaked in
5% trichloroacetic acid (w/v) containing 0.5% (w/v) 12C-L-Lys. Sample
disks were washed three times for 10 min at room temperature in 5%
trichloroacetic acid (w/v) containing 0.5% (w/v) 12C-L-Lys, dried at
80 °C, and the level of [14C]L-Lys-tRNA quantified by the addition of
liquid scintillant (Ultima Gold, Packard Corp.) and scintillation count-
ing. Analogues were added as indicated during determination of Ki
values and [14C]L-Lys adjusted so that concentrations varied between
0.2 and 5 times the apparent Km. The direct attachment of analogues to
in vitro transcribed tRNALys1 was monitored as described earlier (26).
Transcript tRNALys from B. burgdorferi and pure tRNALys from E. coli
were radiolabeled by an [-32P]ATP-PPi exchange reaction catalyzed by
the E. coli tRNA-terminal nucleotidyltransferase (27). The aminoacy-
lation reaction was performed in the presence of 0.1 M B. burgdorferi
LysRS1 or 10 nM E. coli LysRS2, 10 mM of lysine or analogues, 2 M
radiolabeled transcript from B. burgdorferi, or a trace of pure 3-radio-
labeled tRNALys from E. coli with 1.3 mg/ml of total tRNA. Following 30
min of incubation at 37 °C, an aliquot was removed and treated with
RNase P1. The liberated [-32P]AMP and aminoacyl-[-32P]AMP were
separated by TLC and visualized as described previously (26). The
levels of tRNA charging are uniformly low (10%) as a result of signif-
icant loss of activity during the labeling and purification of both E. coli
and B. burgdorferi tRNALys (both tRNAs are 80–90% active initially).
This problem is, to date, unique to tRNALys as both tRNAPhe 2 and
tRNAAla (26) retain 40–50% activity during the same procedure.
Ki Determination—To determine Ki values for lysine analogues, at
least five different concentrations of analogues were first screened in
the aminoacylation reaction under standard conditions with 10 or 4.5
M of [14C]L-Lys for LysRS1 and LysRS2, respectively. Analogue con-
centrations were then established, at which the initial rate of amino-
acylation was decreased by 20–50% when compared with the reaction
lacking analogue, and these levels were used for Ki determinations.
Concentrations of analogues used to determine the Ki for LysRS1 and
LysRS2 were, respectively: 150 or 100 M L-lysine hydroxamate; 650 or
25 M S-(2-aminoethyl)-L-cysteine (AEC); 650 or 50 M L-lysinamide;
400 or 250 M L-lysine methyl ester; 250 or 100 M L-lysine ethyl ester;
650 M or 1 mM DL-5-hydroxylysine; 2.5 or 5 mM L-ornithine; 4 or 40 mM
D-lysine; 200 or 500 M L-cadaverine; 20 or 25 nM lysyl-sulfamoyl
adenosine; 8 or 40 mM L--aminobutyric acid; 2 or 200 mM L--aminobu-
tyric acid; 2.5 or 30 mM L-arginine; 10 or 50 mM L-glutamic acid. In all
cases, stock solutions of inhibitors were maintained at neutral pH. The
Ki values presented represent the average of at least two independent
experiments for LysRS1 and three independent experiments for Ly-
sRS2 where values deviated by no more than 10% between individual
determinations.
In Vivo Growth Inhibition—B. subtilis strains 168 and 157.1 were
grown aerobically in LB medium until A600  1. 1 ml of this culture was
then spun down and washed and resuspended in 1 ml of Spizizen’s
minimal medium. 250 l of these cells were then inoculated in 25 ml of
Spizizen’s minimal medium supplemented with 2 mM L-lysine or 5 M of
AEC or 400 mM L--aminobutyric acid at 37 °C.
RESULTS
Inhibition of LysRS1- and LysRS2-catalyzed in Vitro Amino-
acylation—The aaRS-catalyzed aminoacylation of tRNA is a
two-step reaction. In the first step, an amino acid is activated to
form an enzyme-bound aminoacyl adenylate. The second step
of the reaction involves binding of this complex by tRNA, whose
3-end is then esterified with the aminoacyl moiety followed by
release of the resulting aminoacyl-tRNA. Although LysRS1 and
LysRS2 both utilize this overall reaction mechanism, they
show a key difference at the first step; lysyl-adenylate synthe-
sis by LysRS1 requires the presence of tRNA, whereas LysRS2
can perform the reaction in the absence of tRNA. Given this
difference between LysRS1 and LysRS2, we chose to compare
their ability to recognize lysine and lysyl-adenylate analogues
by determining the kinetics of inhibition of steady-state ami-
noacylation. This approach, rather than measurement of the
inhibition of amino acid activation, would then allow more
direct comparisons to be made between the two systems.
All compounds tested (Fig. 1) were found to act as competi-
tive inhibitors of both LysRS1 and LysRS2, as judged by the
observation of significant changes in Km but not kcat when
2 M. Ibba and H. Roy, unpublished results.
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comparing steady-state aminoacylation kinetic parameters
with and without the addition of analogues (Table I). The most
potent inhibitor of both LysRS1 and LysRS2 was the lysyl-
adenylate analogue lysylsulfamoyl-adenosine, which inhibited
both enzymes equally well (Table I). Analogues of L-lysine,
rather than the adenylate derivative, were less potent inhibi-
tors with Ki values ranging from low M (3.9 M for AEC with
LysRS2) to low mM (12 mM for D-lysine with LysRS2). The least
effective inhibitors were the noncognate amino acids, whose Ki
values varied from 5 mM (L-arginine with LysRS1) to 470 mM
(L--aminobutyric acid with LysRS2).
For LysRS2, the Km for lysine (28) and Ki values for compet-
itors determined in this study generally correlated well with
previously determined values where comparable data exists.
For AEC (29), lysinamide (30), lysine methyl ester (30), lysine
ethyl ester (30), ornithine (31), and cadaverine (28), previously
determined Ki values for aminoacylation by LysRS2 are all
within 1–5-fold of the values reported here. The only exception
is D-lysine, where the previously reported value of 220 M (30)
is over 50-fold lower than the Ki determined here. For other
compounds tested, either kinetic parameters were only deter-
mined previously in the amino acid activation reaction (5-
hydroxylysine, lysine hydroxamate (32)) or no other data are, to
the best of our knowledge, currently available. For LysRS1,
although we recently reported (in Ref. 22 and accompanying
inhibition plots) that AEC acts a competitive inhibitor with a
nearly identical Ki to that described here, no other kinetic
parameters for the inhibition of aminoacylation have been re-
ported for comparison.
Growth Inhibition by Lysine Analogues—Comparison of the
kinetics of inhibition of in vitro aminoacylation by LysRS1 and
LysRS2 indicated that several compounds preferentially in-
hibit one form of LysRS rather than the other. Lysine ana-
logues with the strongest preferences were lysinamide and
FIG. 1. Structures of L-lysine and analogues. Geometries of structures were optimized using ArgusLab 3.1 (Planaria Software). Carbon,
nitrogen, oxygen, sulfur, and hydrogen atoms are represented in gray, blue, red, yellow, and white, respectively.
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AEC, which showed 180- and 290-fold, respectively, lower Ki
values for LysRS2 than LysRS1, and -aminobutyric acid,
which had a 60-fold lower Ki for LysRS1 than LysRS2 (Table I).
To investigate whether these in vitro differences could be cor-
related with specific in vivo growth phenotypes, two related
strains of B. subtilis were employed. 168 is a wild-type strain
that employs LysRS2 for lysyl-tRNA synthesis, and 157.1 is a
derivative of 168, where the endogenous LysRS2-encoding gene
has been replaced by a gene encoding B. burgdorferi LysRS1
(22). The growth of these strains in minimal medium was
monitored with and without the addition of varying concentra-
tions of AEC, lysinamide, and -aminobutyric acid. Addition of
lysinamide at concentrations up to 46 mM had no detectable
effect on the growth rates of either strain 168 or 157.1 (data not
shown). Growth in the presence of 5 M AEC completely pre-
vented growth of 168 but only resulted in an 50% reduction in
the growth rate of 157.1 (Fig. 2A). Conversely, the addition of
400 mM -aminobutyric acid completely inhibited the growth of
157.1 but only lowered the growth rate of 168 by about 50%
(Fig. 2B). These results are consistent with data from in vitro
steady-state kinetics, confirming the selectivity of AEC and
-aminobutyric acid as preferential inhibitors of LysRS2 and
LysRS1, respectively.
Aminoacylation with Noncognate Amino Acids Using Ly-
sRS1 and LysRS2—Previous studies of E. coli LysRS2 (lysS-
encoded) showed that the enzyme is able to activate, amino-
acylate and edit a number of noncognate amino acids (33), and
we have shown previously (22) that AEC is a substrate for
aminoacylation by LysRS1. We investigated the ability of Ly-
sRS1 and LysRS2 to aminoacylate tRNALys with a number of
naturally occurring noncognate amino acids shown above to be
competitive inhibitors of the enzyme. Of the analogues tested,
L-lysine methyl ester, L-lysine ethyl ester, AEC, and, to a lesser
extent, L-ornithine were found to be substrates for aminoacy-
lation of tRNALys by LysRS1 (Fig. 3B). LysRS2 displayed a
significantly broader substrate spectrum, catalyzing aminoacy-
lation with D-lysine, L-lysine methyl ester, L-lysine ethyl ester,
L-ornithine, AEC, L-lysine hydroxamate, L--aminobutyric acid,
and, to a lesser extent, lysinamide, arginine, and glutamate
(Fig. 3A).
Active Site Homology Plots—The ability of certain com-
pounds to selectively inhibit B. burgdorferi LysRS1 or E. coli
LysRS2 in vitro and B. burgdorferi LysRS1 or B. subtilis Ly-
sRS2 in vivo suggests differences between the active site archi-
tectures of the two enzymes. To estimate the degree to which
this divergent substrate discrimination might be conserved,
sequence alignments were constructed from 44 LysRS1 and
137 representative LysRS2 predicted protein sequences using
ClustalX (34). Conservation of amino acids (identity) was then
scored for each position in the two LysRS alignments. These
data were mapped onto the three-dimensional structures of E.
coli LysRS2 (lysS) (35) and P. horikoshii LysRS1 (17) (Fig. 4, A
and B). Examination of the three-dimensional identity plots for
both LysRS1 and LysRS2 showed a strikingly high degree of
conservation throughout the lysine-binding sites of both pro-
teins (Fig. 4, A and B). This conservation of residues was seen
in regions binding both the R-groups and the remainder of the
lysine molecules, suggesting that the patterns of noncognate
amino acid discrimination observed above might be conserved
in the LysRS1 and LysRS2 protein families.
DISCUSSION
Comparison of Amino Acid Discrimination by LysRS1 and
LysRS2—The inhibition of aminoacylation by lysine analogues
suggests several key similarities and differences between the
two forms of LysRS. Both LysRSs showed a comparably strong
enantiomeric selectivity for L-lysine over D-lysine, consistent
with the general observation that L-amino acids are strongly
favored throughout protein synthesis (Ref. 36 and references
therein). Although LysRS2 was able to more easily aminoacy-
late tRNALys with D-lysine (Fig. 3A), the level of D-lysine re-
quired was significantly higher than would be expected in vivo
given estimates of microbial total lysine pools under normal
growth conditions (37). Similarly, the levels of arginine and
ornithine required for the inhibition of aminoacylation by both
LysRS1 and LysRS2 are significantly higher than have been
observed in vivo (38), indicating an adequate level of discrim-
ination by both enzymes. Estimates of cellular concentrations
of cadaverine are comparable with the Ki values determined
here, indicating specific protection exists against cadaverine
TABLE I
Kinetic parameters for the inhibition of steady-state aminoacylation by B. burgdorferi LysRS1 and E. coli LysRS2 (lysS encoded)
Analogue
Ki
a
Ki LysRS1/Ki LysRS2
kcat (R)
b
LysRS1 LysRS2 LysRS1 LysRS2
M M
L-Lysine hydroxamate 360  70 86  7 4 1.1  0.06 0.7  0.02
S-(2-Aminoethyl)-L-cysteine 1140  230 3.9  0.4 290 1  0.09 0.8  0.02
L-Lysinamide 2120  450 17  2 180 1  0.07 1.1  0.01
L-Lysine methyl ester 478  100 74  7 6 1  0.07 0.8  0.03
L-Lysine ethyl ester 303  45 55  6 6 1.1  0.05 0.8  0.02
DL-5-Hydroxylysine 1200  140 500  52 2 1.2  0.03 0.8  0.02
L-Ornithine 8800  1300 6300  600 1 1.1  0.02 0.9  0.02
D-Lysine 6900  2500 12,000  1400 1 1.1  0.1 0.7  0.04
L-Cadaverine 320  45 260  28 1 0.9  0.03 1  0.03
Lysyl-sulfamoyl adenosine 0.025  0.004 0.028  0.003 1 1  0.05 0.9  0.03
L--Amino butyric acid 21,200  5300 14,200  1700 1 1.1  0.09 1.2  0.02
L--Aminobutyric acid 8040  2200 470,000  51,000 0.02 1  0.07 1  0.02
L-Arginine 5060  860 64,000  5000 0.08 1.1  0.04 0.9  0.03
L-Glutamic acid 37,000  7800 130,000  13,000 0.3 0.9  0.06 1.2  0.03
Km kcat
LysRS1 LysRS2 LysRS1 LysRS2
M s1
L-Lysine 34  3 2.6  0.2 0.06  0.002 1.84  0.02
a Ki values were determined from the following formula Km(app)  Km(real) (1  [inhibitor]/Ki), using the Km values shown and inhibitor
concentrations indicated in the text.
b kcat determined in the presence of inhibitor relative to kcat in the absence of inhibitor.
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FIG. 3. TLC analysis of tRNALys ami-
noacylation with lysine analogues by
(A) E. coli LysRS2 or (B) B. burgdor-
feri LysRS1. Lane 1, L-lysine hydroxam-
ate; lane 2, S-(2-aminoethyl)-L-cysteine;
lane 3, L-lysinamide; lane 4, L-lysine
methyl ester; lane 5, L-lysine ethyl ester;
lane 6, DL-5-hydroxylysine; lane 7, L-orni-
thine; lane 8, D-lysine; lane 9, L-cadaver-
ine; lane 10, L--aminobutyric acid; lane
11, L--aminobutyric acid; lane 12, L-argi-
nine; lane 13, L-glutamic acid; lane 14,
L-glutamine; lane 15, L-lysine; lane 16,
without amino acid. The samples were
spotted on 10-cm polyethylenimine-cellu-
lose plates (Sigma) prewashed and sepa-
rated by TLC in glacial acetic acid/1 M
NH4Cl/H2O (5:10:85). The significant pro-
portion of uncharged tRNA reflects the
low aminoacylation acceptance activity of
tRNALys after labeling and purification
(see “Experimental Procedures”).
FIG. 2. In vivo growth inhibition of B. subtilis strains 168 (A) and 157.1 (B). Spizizen’s minimal medium supplemented with 2 mM L-lysine
(E), 5 M AEC (), or 400 mM L--aminobutyric acid () were inoculated with B. subtilis strain 168 or 157.1, and growth was monitored by
absorbance at 600 nm. Each curve represents the average of at least three independent experiments with standard deviation indicated to each time
point.
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inhibition at normal lysine levels as proposed previously (28).
Although the Ki values are significantly higher for L-glutamic
acid than most of the other compounds tested, they are in fact
not far removed from microbial glutamate concentrations,
which may typically reach up to 80 mM or higher under certain
growth conditions (e.g. 39). Taken together, our data confirmed
that LysRS1 and LysRS2 are equally adept at discriminating
against both the more common lysine analogues and the non-
cognate canonical amino acids. The ability to discriminate ly-
sine from several of the analogues tested here was also recently
described for the L box of B. subtilis, a lysine-responsive leader
RNA that directly binds lysine, indicating that RNA and pro-
tein based systems offer equally effective mechanisms for spe-
cific recognition of lysine (40, 41).
Among the other amino acids tested, all but one showed
higher Ki values for LysRS1 than for LysRS2, in agreement
with the more compact binding pocket for the lysine backbone
predicted from the structure of the class I enzyme (Fig. 4C).
L-Lysine hydroxamate, L-lysine methyl ester, L-lysine ethyl es-
ter, and DL-5-hydroxylysine all show a marginal preference for
inhibition of LysRS2 over LysRS1, with the Ki values 2–6-fold
higher for the class I enzyme, whereas L--aminobutyric acid
inhibits both enzymes to a similar degree. In contrast, AEC,
L-lysinamide, and L--aminobutyric acid were all found to be
highly specific for a particular form of LysRS. AEC and lysin-
amide both show preferential inhibition of LysRS2 over Ly-
sRS1, with the Ki values being 290- and 180-fold lower for the
class II enzyme, respectively. The differences in AEC and lysi-
namide recognition reflect the more closed structure of LysRS1
around the amino acid backbone, where two conserved aro-
matic residues make hydrophobic interactions with the side
chain as opposed to a single residue in LysRS2 (Fig. 4, B and
C). The role of these residues is illustrated from modeling the
binding of AEC at both active sites. In LysRS1, which binds
AEC relatively poorly, there is some steric exclusion of the
sulfur atom by His-240 (Fig. 4C). In contrast, the orientation of
bound AEC and the absence of a second “packing” residue in
LysRS2 allow inhibitor binding without a potential steric clash
(Fig. 4D), in agreement with the relatively strong binding of
AEC. The importance of Trp-218 and His-240 in LysRS1 may
be even more pronounced than is initially apparent from the
existing tRNA-free structure. In a docking model of Pyrococcus
horikoshii LysRS1 and tRNA (17), Trp-218 and His-240 (Trp-
220 and His-242 in B. burgdorferi) make stacking interactions
with the terminal adenosine of tRNA suggesting that they may
be more closely packed in the active site during aminoacyla-
FIG. 4. L-Lysine and S-(2-amin-
oethyl)-L-cysteine recognition by Ly-
sRS1 and LysRS2. A, L-lysine in the ac-
tive site of P. horikoshii LysRS1. B,
L-lysine in the active site of E. coli Ly-
sRS2. C, model for the binding of S-(2-
aminoethyl)-L-cysteine to the active site of
P. horikoshii LysRS1. D, model for the
binding of S-(2-aminoethyl)-L-cysteine to
the active site of E. coli LysRS2. For C
and D, the lysine ligand was modified to
present an S instead of the C, and the
energy of the resulting structures was
minimized using Swiss-Pdb Viewer ver-
sion 3.7. The resulting models were visu-
alized in stick and van der Waals surface
for active site residues and ball and stick
for S-(2-aminoethyl)-L-cysteine in MOL-
MOL version 2k.2 (44). The residues are
colored according to their conservation in
corresponding sequence alignments: gold,
100% identity; red, 81–99%; pink,
61–80%; white, 41–60%. For the sub-
strate lysine, the backbone is shown in
white, and oxygen, nitrogen, and sulfur
are colored red, blue, and yellow,
respectively.
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tion. Such tRNA-mediated rearrangements of active site resi-
dues have been observed previously in other class I aaRSs that,
like LysRS1, require tRNA for amino acid activation (18–20,
42).
Of all the compounds compared as inhibitors of LysRS1 and
LysRS2, only L--aminobutyric acid was a significantly better
inhibitor of the class I enzyme. Examination of LysRS1 and
LysRS2 active sites offers no obvious structural basis for this
difference, although the relatively high Ki values compared
with most of the other analogues may be indicative of poor
binding in both cases. Although the kinetics of inhibition by
L--aminobutyric acid suggest that neither form of LysRS
binds this analogue well, in vivo data (discussed below) indi-
cate that the difference in discrimination may be functionally
significant.
LysRS1 Displays a Narrower Substrate Spectrum than Ly-
sRS2—The high degree of conservation of both LysRS1 and
LysRS2 active site residues (Fig. 4, A and B) suggests that their
marked differences in sensitivity to numerous inhibitors may
be of functional significance. This was strongly supported by
aminoacylation data, which showed that a far wider range of
analogues could be stably attached to tRNALys by LysRS2 than
by LysRS1. This difference could reflect the existence of a more
proficient proofreading activity in LysRS1 or a more promiscu-
ous active site in LysRS2. The possibility that proofreading
prevents accumulation of mischarged tRNAs was not sup-
ported by our initial studies with LysRS12 and would not be
expected given that the closely related class 1b aaRSs glutami-
nyl- and glutamyl-tRNA synthetases have not been shown to
catalyze such activities (reviewed in Ref. 4). Thus, the differ-
ence in substrate profiles between LysRS1 and LysRS2 can be
attributed to a higher degree of substrate discrimination in the
class I enzyme. This is in agreement with our recent study
employing AEC, which suggested that inefficient analogue rec-
ognition by LysRS1 could prevent miscoding of lysine codons
during protein synthesis (22). The data presented here sup-
ports this finding and suggests that this function in translation
might also extend to other analogues, given the generally nar-
rower substrate specificity of LysRS1. One important exception
is L--aminobutyric acid, whose ability to preferentially inhibit
LysRS1 indicates LysRS2 can also function in translational
quality control by excluding particular noncognate amino ac-
ids. This was confirmed by the observation that production of
LysRS2 allows growth of bacterial cells at L--aminobutyric
acid concentrations inhibitory to cells producing solely LysRS1.
It is worth noting, however, that any practical application of
this difference in analogue recognition is dependent on the
discovery of specific inhibitors of LysRS1 with Ki values several
orders of magnitude lower than L--aminobutyric acid.
Functional Consequences of Divergent Recognition of Non-
cognate Amino Acids—The finding that LysRS1 and LysRS2
have substantially different noncognate amino acid substrate
profiles has functional, evolutionary, and practical implica-
tions. Earlier work indicated that LysRS1 could prevent infil-
tration of the genetic code by AEC, but that now appears to
simply be an example of a more general phenomenon whereby
both forms of LysRS can provide translational quality control
under appropriate conditions. The exact nature of the physio-
logical conditions when such quality control might be critical
awaits determination of lysine analogue pools in archaeal and
bacterial metabolomes. LysRS-mediated quality control relies
on the presence of one LysRS or the other but not both together,
in agreement with the phylogenetic distributions observed for
the majority of LysRS1 and LysRS2 sequences for which the
corresponding complete genome sequences are known. Of the
over 240 complete genome sequences publicly available, only
five encode both LysRS1 and LysRS2. Four examples are from
the Methanosarcinaceae, where LysRS1 and LysRS2 appar-
ently function together in suppressor tRNA charging (15), and
the other is Bacillus cereus, where it is unclear if both LysRSs
are produced.3 In addition to providing a rationale for the
existence and distribution of the two LysRSs, the divergence in
substrate recognition confirms earlier proposals that LysRS1
may be a suitable target for the development of novel anti-
microbials (43). LysRS1 is found alone in a number of bacterial
pathogens (e.g. B. burgdorferi, various Brucella and Rickettsia
species, Treponema pallidum, and Tropheryma whippelii), and
our findings indicate that it may be practical to target Lys-
tRNALys synthesis in these organisms without disrupting the
LysRS2-mediated pathway of the human host.
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12. Söll, D., Becker, H. D., Plateau, P., Blanquet, S., and Ibba, M. (2000) Proc.
Natl. Acad. Sci. U. S. A. 97, 14224–14228
13. Ambrogelly, A., Korencic, D., and Ibba, M. (2002) J. Bacteriol. 184, 4594–4600
14. O’Donoghue, P., and Luthey-Schulten, Z. (2003) Microbiol. Mol. Biol. Rev. 67,
550–573
15. Polycarpo, C., Ambrogelly, A., Ruan, B., Tumbula-Hansen, D., Ataide, S. F.,
Ishitani, R., Yokoyama, S., Nureki, O., Ibba, M., and Söll, D. (2003) Mol.
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42. Liu, J., Ibba, M., Hong, K. W., and Söll, D. (1998) Biochemistry 37, 9836–9842
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